Institutional members access full text with Ovid®

Share this article on:

Graft-versus-host disease: why have we not made more progress?

Jaglowski, Samantha M.; Devine, Steven M.

Current Opinion in Hematology: March 2014 - Volume 21 - Issue 2 - p 141–147
doi: 10.1097/MOH.0000000000000026
MYELOID DISEASE: Edited by Martin S. Tallman

Purpose of review Although allogeneic hematopoietic stem cell transplantation (allo-SCT) is potentially curative for a number of hematologic malignancies, its use is limited by the development of acute and chronic graft-versus-host disease (GVHD). This potentially fatal complication occurs in approximately 50% of allo-SCT recipients.

Recent findings The pathogenesis of acute and chronic GVHD remains poorly understood, methods to prevent it are largely unchanged over the last two decades, and response to front-line treatment with corticosteroids is suboptimal. For patients with steroid-refractory disease, response to second-line treatment is dismal. The prospective clinical studies evaluating new agents for GVHD have been hampered by the inconsistencies in design, making generalization difficult, and few multicenter studies have been conducted.

Summary Advances have been made over the last decade in grading both acute and chronic GVHD, with the development of biomarkers that provide improved prognostic information in acute GVHD and National Institutes of Health Consensus Criteria for improved grading of chronic GVHD. This, along with the broad understanding of the need to conduct prospective studies with uniform inclusion criteria and endpoints leading to multicenter studies, will hopefully lead to advancements in the prevention of GVHD in the near future.

Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA

Correspondence to Samantha M. Jaglowski, MD, MPH, A352 Starling-Loving Hall, 320 West 10th Avenue, Columbus, OH 43210, USA. E-mail:

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins